Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: A single institution's experience

Aims: To determine the efficacy of the combination of oxaliplatin and capecitabine in patients with advanced colorectal cancer. Materials and Methods: A retrospective review of all patients with advanced colorectal cancer treated with oxaliplatin 130 mg/m(2) on day I and capecitabine 2 g/m(2) daily in two divided doses days 1-14 every 3 weeks, outside of a clinical trial at the Royal Marsden Hospital. Patients could have received any number of lines of previous treatment. Results: Between September 2000 and March 2002, 47 patients were treated with the combination. Fifteen patients had not received previous chemotherapy for advanced disease, 10 had received one line of treatment and 21 had received two or more lines of previous treatment. The overall response rate was 27.6%, with a complete response rate of 2.1%. Overall response rates according to line of treatment were 33% for non pre-treated patients, 36% for second line and 19% for third and more lines. The median overall survival was 13.4 months and the median failure-free survival was 6.5 months. There were no treatment-related deaths and no grade 4 haematological toxicity. Conclusions: The combination of oxaliplatin and capecitabine is active in advanced colorectal cancer. It can result in down-staging of tumours to enable hepatic resection. In addition, it is a well-tolerated regimen. (C) 2003 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.